Does Prolia Cause Bone Fractures After Stopping?
Yes, discontinuing Prolia (denosumab) is linked to a higher risk of multiple vertebral fractures, known as rebound-associated vertebral fractures (RAVFs). This occurs because bone density and strength drop sharply after stopping, often more than before treatment began. Studies show fracture rates of 10-30% within 12-18 months post-discontinuation in postmenopausal women with osteoporosis, compared to 3-5% in those who continue or switch therapies.[1][2]
Why Does This Happen with Prolia?
Prolia inhibits RANKL, a protein that activates bone-breaking osteoclasts, rapidly increasing bone density during use. Stopping abruptly removes this inhibition, causing osteoclasts to surge (up to 6-fold), leading to accelerated bone resorption. This "rebound effect" peaks at 6-12 months and can persist, with bone turnover markers rising higher than pre-treatment levels.[3][4]
How Common Is It and Who Is at Risk?
In clinical trials like FREEDOM's open-label extension, 16.4% of women stopping Prolia after 3 years had new vertebral fractures by month 12, versus 4.1% continuing. Risk factors include longer prior use (≥3 years), lower baseline bone density (T-score ≤-3.0), and prior fractures. Non-vertebral fractures also rise but less dramatically.[1][5]
What Happens If You Stop Prolia Suddenly?
Without follow-up treatment, bone mineral density (BMD) at the spine can fall 6-8% within a year, and total hip BMD by 4-6%. Multiple vertebral fractures often occur silently or with back pain, increasing height loss and kyphosis risk. Case reports document clusters of 3+ fractures shortly after stopping.[2][6]
How to Prevent Fractures After Stopping Prolia
Guidelines recommend immediate transition to bisphosphonates like alendronate or zoledronic acid upon discontinuation, which suppresses the rebound effect and maintains BMD gains. A single zoledronic acid infusion within 6 months post-Prolia reduces vertebral fracture risk by over 70%. Delaying >6 months heightens danger. No off-label "washout" period is advised.[4][7]
Prolia vs. Other Osteoporosis Drugs on Rebound Risk
| Drug | Rebound Fracture Risk After Stopping | Mitigation Strategy |
|------|-------------------------------------|---------------------|
| Prolia (denosumab) | High (10-30% vertebral) | Switch to bisphosphonate immediately |
| Reclast (zoledronic acid) | Low-moderate; residual effects last 1-3 years | Taper dosing |
| Fosamax (alendronate) | Minimal; binds bone long-term | Gradual taper if needed |
| Tymlos/Forteo (anabolics) | None significant | Follow with antiresorptive |
Prolia's shorter half-life (half-life ~25 days) drives the sharp rebound, unlike bisphosphonates' multi-year bone retention.[3][8]
What Patients Report and Real-World Data
Patient forums and registries note back pain, height loss, and ER visits for fractures post-Prolia. A 2023 Danish study of 6,000+ women found 4.5-fold higher multiple vertebral fracture risk in the year after stopping versus non-users. FDA updated Prolia's label in 2023 to warn of this risk.[5][9]
[1]: FREEDOM Extension Trial (NEJM 2017)
[2]: Rebound Fractures Review (JBMR 2019)
[3]: RANKL Mechanism (Nature Reviews 2021)
[4]: Endocrine Society Guidelines (JCEM 2020)
[5]: Danish Cohort Study (Osteoporos Int 2023)
[6]: Case Series (Lancet Diabetes 2018)
[7]: Zoledronic Acid Transition (J Bone Miner Res 2022)
[8]: Drug Comparison (Ther Adv Musculoskelet Dis 2021)
[9]: FDA Label Update (Amgen Prolia PI 2023)